Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies on 17DD-YF primary vaccination performance in patients with AID. This prospective non-interventional study conducted between March and July, 2017 assessed the safety and immunogenicity of planned 17DD-YF primary vaccination in patients with AID. Adult patients with AID (both sexes) were enrolled, along with healthy controls, at a single hospital (Vitória, Brazil). Included patients were referred for planned vaccination by a rheumatologist; in remission, or with low disease activity; and had low level immunosuppression or the attending physician advised interruption of immunosuppression for safety reasons. The occurrence of AE, neutralizing antibody kinetics, seropositivity rates, and 17DD-YF viremia were evaluated at various time points (day 0 (D0), D3, D4, D5, D6, D14, and D28). Individuals evaluated (n = 278), including patients with rheumatoid arthritis (RA; 79), spondyloarthritis (SpA; 59), systemic sclerosis (8), systemic lupus erythematosus (SLE; 27), primary Sjögren's syndrome (SS; 54), and healthy controls (HC; 51). Only mild AE were reported. The frequency of local and systemic AE in patients with AID and HC did not differ significantly (8 vs. 10% and 21 vs. 32%; p = 1.00 and 0.18, respectively). Patients with AID presented late seroconversion profiles according to kinetic timelines of the plaque reduction neutralization test (PRNT). PRNT-determined virus titers (copies/mL) [181 (95% confidence interval (CI), 144-228) vs. 440 (95% CI, 291-665), p = 0.004] and seropositivity rate (78 vs. 96%, p = 0.01) were lower in patients with AID after 28 days, particularly those with SpA (73%) and SLE (73%), relative to HC. The YF viremia peak (RNAnemia) was 5-6 days after vaccination in all groups. In conclusion, consistent seroconversion rates were observed in patients with AID and our findings support that planned 17DD-YF primary vaccination is safe and immunogenic in patients with AID.

Síndrome de Horner secundária a neoplasia de esôfago: relato de caso / Horner's syndrome secondary to esophageal cancer: a case report

A síndrome de Horner resulta de uma lesão das fibras simpáticas destinadas ao olho e classicamente se apresenta com ptose palpebral parcial, miose e anidrose de uma hemiface ipsilateral ao local acometido. As causas mais comuns relacionadas a ela são o traumatismo cirúrgico de estruturas cervicais, dissecção da carótida interna e processos neoplásicos, principalmente tumor de Pancoast, raramente relacionase com neoplasia esofagiana. Neste relato de caso descrito, a paciente apresenta síndrome de Horner secundária a um tumor de esôfago. A atenção ao exame físico e a propedêutica adequada fazem total diferença na detecção desta síndrome necessitando de exames complementares para elucidar a sua etiologia. O tratamento pode ser eficaz quando se detecta precocemente a causa. (AU)

Horner's syndrome results from a lesion of sympathetic fibers to eye and classically presents with partial ptosis, miosis and anhidrosis of the ipsilateral hemifacial the affected site. The most common causes related to it are the surgical trauma of cervical structures, dissection of the internal carotid and neoplastic processes, especially tumor Pancoast, rarely related to esophageal cancer. In this report the case described, the patient has Horner syndrome secondary to esophageal tumor. Attention to physical examination and appropriate workup make all the difference in the detection of this syndrome requiring additional tests to elucidate its etiology. The treatment may be effective if early detect the cause. (AU)